ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

A stem cell therapy to treat Parkinson's disease enters clinical trials

TOKYO -- Stem cells have enormous promise in regenerative medicine, with the potential to treat a range of injuries and diseases, from Parkinson's and cancer to infertility and baldness. The main roadblock, however, has been ethical concerns regarding the use of human embryonic tissue. But now, new technologies are starting to come onto the market that sidestep those issues, opening the door to innovative therapies, as well as identify new drugs by screening using stem cells.

International Stem Cell Corp. (ISCO) will soon start a phase I clinical trial in Australia using the company's ISC-hpNSC, human parthenogenetic stem cell-derived neural stem cells, for the treatment of Parkinson's disease, the second most common neurodegenerative disease.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more